-
Study: Single-injection durolane hylauronic acid safe, effective treatment for knee osteoarthritis
Treating knee arthritis with NASHA (durolane hyaluronic acid) is a safe and effective procedure, according to a study in Open Access Rheumatology: Research and Reviews. -
Who are the 14 major players in the global spine biologics market?
Here are the 14 major players in the global spine biologics market, according to an E Market Research report. -
Cerapedics i-FACTOR yields 50% fusion rate vs. 20% for allograft at 1-year follow-up — 3 insights
Mikkel O. Andersen, MD, of Middelfart Hospital in Denmark, reported results from the IVANOS study investigating Cerapedics' i-FACTOR Peptide Enhanced Bone Graft. -
3 things to know about Burst Biologics
Burst Biologics, based in Boise, Idaho, is a regenerative medicine company. -
Patients duped by non-FDA approved stem cell marketing: 8 things to know
Orthopedic surgeons continue to express concerns over various stem cell treatments being offered to patients, according to Contact7. -
Crowdfunding for stem cell treatments may spread misinformation: 4 insights
Insurers will not usually pay for unproven stem cell treatments, so patients seeking those interventions must pay out-of-pocket or use social media to receive donations, a practice known as crowdfunding. Medical crowdfunding campaigns may convey misleading messages about stem cell-based interventions, according to a JAMA study. -
4 things to know about NuVasive's AttraX Putty
NuVasive's biologics portfolio includes AttraX Putty. -
Target stem cells to stop osteoarthritis progression, study suggests: 3 insights
Osteoarthritis-mesenchymal stem cells may drive cartilage degeneration pathogenesis and should be targeted in osteoarthritis therapy, according to a study in Scientific Reports. -
Stem cell-derived neurons survive grafting into spinal cord injury in animal study: 3 things to know
Researchers successfully grafted induced pluripotent stem cell-derived neural precursor cells into the spinal cords of pigs with and without spinal cord injury with only temporary immunosuppression, according to a study in Science Translational Medicine. -
FDA seeks to shut down stem cell clinics offering unapproved treatments: 5 insights
The U.S. Department of Justice filed lawsuits to shut down stem cell clinics in Florida and California that marketed unapproved stem cell treatments, the Los Angeles Times reports. -
Transplanted spinal cord stem cells may help ALS sufferers: 4 insights
Transplanted human spinal cord-derived neural stem cells may stabilize functioning in amyotrophic lateral sclerosis patients, according to a study in the Annals of Clinical and Translational Neurology. -
Global spine biologics market to hit $2.7B by 2023: 3 observations
The global spine biologics market will likely grow at a compound annual growth rate of 4.5 percent between 2018 and 2023, based on a Market.biz report, according to Business News. -
6 things to know about Bone Biologics
Bone Biologics, based in Burlington, Mass., is a publicly traded company focused on orthobiologic solutions. -
Dr. Luga Podesta on stem cells in orthopedics, 'a new frontier in medicine'
Luga Podesta, MD, is a sports medicine and regenerative orthopedic specialist at Bluetail Medical Group in Naples, Fla. He was the lead author in a 2013 study in The American Journal of Sports Medicine which demonstrated that platelet-rich plasma can effectively treat partial UCL tears in athletes. In a recent interview with Becker's Spine Review, Dr. Podesta spoke about the possibilities and pitfalls of stem cell therapies in orthopedics and trends in regenerative medicine. -
Who are the 15 major players in the global orthobiologics market?
The global orthobiologics market is expected to grow from $4.66 billion in 2017 to reach $8.06 billion by 2023, increasing at a 5.7 percent compound annual growth rate, according to a Market.Biz report. -
Tissue Regenix group inks deal, expands DermaPure access in US
U.K.-based Tissue Regenix Group inked a deal with Premier for TRX's flagship product DermaPure to maintain access to 3,900 hospitals and more than 150,000 healthcare providers in the U.S., according to proactiveinvestors UK. -
Biologica Technologies to exhibit ProteiOS data at AANS Annual Meeting: 3 insights
Biologica Technologies will exhibit clinical data for its ProteiOS growth factor at the American Association of Neurological Surgeons Annual Scientific Meeting in New Orleans. -
Infuse gets new FDA indication for lateral, anterior spinal fusions with PEEK implants: 5 things to know
Medtronic received FDA clearance for a new indication with its Infuse Bone Graft. -
Dr. Domagoj Coric treats 1st patient in DiscGenics' trial to treat degenerative disc disease: 5 insights
The phase I/II U.S. clinical trial testing DiscGenics' IDCT for treating degenerative disc disease is underway. -
4 things to know about Datum Orthobiologics, a newly formed company
Datum Orthobiologics was recently founded to provide orthopedic ossification, bone formation and tissue regeneration solutions.
Page 32 of 34